2 suspended, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Suspended 2, Recruiting 1 |
Follow Huda Salman: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant CD4CAR - Acute Myeloid Leukemia | Phase 1 | Suspended | Huda Salman | 30 | 2024-03-19 | 2026-09-30 |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. CD4CAR - Chronic Myelomonocytic Leukemia | Phase 1 | Suspended | Huda Salman | 30 | 2024-02-21 | 2026-09-24 |
| CD4CAR for CD4+ Leukemia and Lymphoma CD4CAR - T-cell Lymphoma, T-cell Leukemia | Phase 1 | Recruiting | Huda Salman | 20 | 2020-07-09 | 2026-06-24 |
Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, T-Cell (1) · Lymphoma (1) · Lymphoma, T-Cell (1)
United States (3)